Please assess the completion status of the following clinical trial:

Trial Title: The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Body mass index (BMI) ≤ 45 kg/m2~2. Fasting Triglycerides (TG) ≥ 500 mg/dL (≥ 5.7 mmol/L) at Screening.~3. If on statin or fibrate, participants must be on stable, labeled dose for at least 3 months prior to screening. Participants not receiving these drugs within 4 weeks prior to screening are also eligible.~Exclusion Criteria:~1. Type 1 diabetes mellitus~2. Newly diagnosed type 2 diabetes mellitus (within 12 weeks of screening) or HbA1c ≥ 9.0% at Screening~3. Acute pancreatitis within 3 months of screening~4. Acute Coronary Syndrome within 6 months of screening~5. Major surgery within 3 months of screening~6. Prior exposure to ISIS 304801~7. Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
- Volanesorsen 300 mg weekly (Type: EXPERIMENTAL): Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks.
- Volanesorsen 300 mg biweekly, post Week 13 (Type: EXPERIMENTAL): Volanesorsen 300 mg administered subcutaneously once-weekly for 13 weeks, then bi-weekly for 13 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).